• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Interleukin named in patent suit by Australian genetic testing firm

Interleukin named in patent suit by Australian genetic testing firm

March 2, 2010 By MassDevice staff

Interleukin Genetics Inc. (NYSE:ILI) and seven other firms were named in a patent infringement lawsuit filed by an Australian genetic testing company.

Genetic Technologies Ltd. of Victoria, Australia, asserts that Interleukin is one of eight companies violating a patent it holds for “Intron Sequence Analysis Method for Detection of Adjacent Locus Alleles as Haplotypes,” according to documents filed in the U.S. District Court for Western Wisconsin.

Beckman Coulter Inc. (NYSE:BEC) was also named in the suit, which alleges that each of the companies developed products that infringe on one or more claims held in U.S. Patent No. 5,612,179, which Genetic Technologies was granted in May 1997.

“Defendant Interleukin offers and provides one or more genetic risk assessment testing services that utilize the methods set forth in one or more claims of the ‘179 Patent,” according to the complaint. More specifically, Interleukin is alleged to have violated Genetic Technologies’ patent with its PST susceptability test for periodontal gum disease.

Interleukin claims the PST test to be the “first and only genetic test that analyzes two interleukin 1 (IL1) genes for variations that identify an individual’s predisposition for over-expression of inflammation and risk for periodontal disease,” according to the company’s website.

Interleukin said it hasn’t been served with the complaint, which was filed Feb. 10, according to regulatory documents filed with the federal Securities & Exchange Commission. But company officials said the firm was approached by Genetics Technologies the day it filed suit with a draft license agreement in exchange for a “yet undetermined fee,” according to the filing.

Officials said they believed the company has a substantial defense against the claims.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well Tagged With: Interleukin Genetics Inc.

More recent news

  • SS Innovations completes first robotic telesurgery for weight loss
  • Johnson & Johnson MedTech adds new CMO for its Electrophysiology business
  • Abbott earns Medicare win for TriClip TEER system
  • Judge says Johnson & Johnson Ethicon owes $76.6M to ChemImage after failed partnership
  • Aurora Spine begins first procedures with Aero lumbar fusion system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy